


1 Gefitinib

2 ゲフィチニブ



3

4 $C_{22}H_{24}ClFN_4O_3$: 446.90

5 *N*-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-

6 4-yl)propoxy]quinazolin-4-amine

7 [184475-35-2]

8

9 Gefitinib contains not less than 98.0% and not more
10 than 102.0% of gefitinib ($C_{22}H_{24}ClFN_4O_3$), calculated
11 on the anhydrous basis.

12 **Description** Gefitinib occurs as a white powder.

13 It is slightly soluble in ethanol (99.5), and practically in-
14 soluble in water.

15 **Identification** (1) Determine the absorption spectrum
16 of a solution of Gefitinib in a mixture of trifluoroacetic acid
17 solution (1 in 500) and acetonitrile (3:2) (1 in 100,000) as
18 directed under Ultraviolet-visible Spectrophotometry
19 <2.24>, and compare the spectrum with the Reference Spec-
20 trum or the spectrum of a solution of Gefitinib RS prepared
21 in the same manner as the sample solution: both spectra ex-
22 hibit similar intensities of absorption at the same wave-
23 lengths.

24 (2) Determine the infrared absorption spectrum of Ge-
25 fitinib as directed in the diffuse reflectance method or the
26 potassium bromide disk method under Infrared Spectrome-
27 try <2.25>, and compare the spectrum with the Reference
28 Spectrum: both spectra exhibit similar intensities of absorp-
29 tion at the same wave numbers.

30 **Purity** (1) Heavy metals—Being specified separately
31 when the drug is granted approval based on the Law.

32 (2) Related substances—Use the sample solution ob-
33 tained in the Assay as the sample solution. Pipet 1 mL of
34 the sample solution, add a mixture of trifluoroacetic acid
35 solution (1 in 500) and acetonitrile (3:2) to make exactly
36 100 mL. Pipet 1 mL of this solution, and add a mixture of
37 trifluoroacetic acid solution (1 in 500) and acetonitrile (3:2)
38 to make exactly 10 mL, and use this solution as the standard
39 solution. Perform the test with exactly 5 μ L each of the sam-
40 ple solution and standard solution as directed under Liquid
41 Chromatography <2.01> according to the following condi-
42 tions, and determine each peak area by the automatic inte-
43 gration method: the peak area of the related substance A

44 having the relative retention time of about 0.13 to gefitinib
45 from the sample solution is not larger than the peak area of
46 gefitinib from the standard solution, the peak area of the re-
47 lated substance B having the relative retention time of about
48 1.3 from the sample solution is not larger than 2 times the
49 peak area of gefitinib from the standard solution, and the
50 area of the peak other than gefitinib and the peaks men-
51 tioned above from the sample solution is not larger than the
52 peak area of gefitinib from the standard solution. Further-
53 more, the total area of the peaks other than gefitinib from
54 the sample solution is not larger than 4 times the peak area
55 of gefitinib from the standard solution.

56 **Operating conditions**—

57 Detector, column, column temperature, mobile phase,
58 and flow rate: Proceed as directed in the operating
59 conditions in the Assay.

60 Time span of measurement: About 5 times as long as the
61 retention time of gefitinib, beginning after the solvent peak.

62 **System suitability**—

63 System performance: Proceed as directed in the system
64 suitability in the Assay.

65 Test for required detectability: Pipet 5 mL of the standard
66 solution, and add a mixture of trifluoroacetic acid solution
67 (1 in 500) and acetonitrile (3:2) to make exactly 10 mL.
68 When the procedure is run with 5 μ L of this solution under
69 the above operating conditions, the SN ratio of the peak of
70 gefitinib is not less than 10.

71 System repeatability: When the test is repeated 6 times
72 with 5 μ L of the standard solution under the above operating
73 conditions, the relative standard deviation of the peak area
74 of gefitinib is not more than 2.0%.

75 **Water** <2.48> Not more than 0.4% (0.1 g, coulometric ti-
76 tration).

77 **Residue on ignition** <2.44> Not more than 0.2% (1.0 g,
78 platinum crucible).

79 **Assay** Weigh accurately about 35 mg each of Gefitinib
80 and Gefitinib RS (separately determine the water <2.48> in
81 the same manner as Gefitinib), add 85 mL of a mixture of
82 trifluoroacetic acid solution (1 in 500) and acetonitrile (3:2)
83 to each, sonicate to dissolve, add a mixture of trifluoroacetic
84 acid solution (1 in 500) and acetonitrile (3:2) to make ex-
85 actly 100 mL, and use these solutions as the sample solution
86 and the standard solution, respectively. Perform the test
87 with exactly 5 μ L each of the sample solution and standard
88 solution as directed under Liquid Chromatography <2.01>
89 according to the following conditions, and determine the
90 peak areas, A_T and A_S , of gefitinib in each solution.

$$91 \text{ Amount (mg) of gefitinib (C}_{22}\text{H}_{24}\text{ClFN}_4\text{O}_3) \\ 92 = M_S \times A_T / A_S$$

93 M_5 : Amount (mg) of Gefitinib RS taken, calculated on
94 the anhydrous basis

95 *Operating conditions*—

96 Detector: An ultraviolet absorption photometer
97 (wavelength: 247 nm).

98 Column: A stainless steel column 3 mm in inside
99 diameter and 10 cm in length, packed with
100 octadesylsilanized silica gel for liquid chromatography (3
101 μm in particle diameter).

102 Column temperature: A constant temperature of about
103 60°C.

104 Mobile phase: A mixture of ammonium acetate solution
105 (3 in 310) and acetonitrile (31:19).

106 Flow rate: 0.9 mL per minute (the retention time of
107 gefitinib is about 5.5 min).

108 *System suitability*—

109 System performance: Dissolve 15 mg of 3,4-
110 dichloroaniline in 60 mL of the standard solution. When the
111 procedure is run with 5 μL of this solution under the above
112 operating conditions, 3,4-dichloroaniline and gefitinib are
113 eluted in this order with the resolution between these peaks
114 being not less than 5.


115 System repeatability: When the test is repeated 6 times
116 with 5 μL of the standard solution under the above operating
117 conditions, the relative standard deviation of the peak area
118 of gefitinib is not more than 1.0%.

119 **Containers and storage** Containers—Tight containers.

120 **Others**

121 Related substance A:

122 7-Methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-
123 4(3*H*)-one




124

125

126 Related substance B:

127 *N*-(4-Chloro-3-fluorophenyl)-7-methoxy-6-[3-(morpholin-
128 4-yl)propoxy]quinazolin-4-amine



129

130

131 *Add the following to 9.01 Reference*

132 *Standards (1):*

133 **Gefitinib RS**

134 *Add the following to 9.41 Reagents,*

135 *Test Solutions:*

136 **3,4-dichloroaniline** $\text{C}_6\text{H}_3\text{Cl}_2\text{N}$ A white to brown
137 solid.

138 *Melting point* <2.60>: 69 – 75°C

139